TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate‑induced growth inhibition in pancreatic cancer cells

Ikejiri,Fumiyoshi; Honma,Yoshio; Kasukabe,Takashi; Urano,Takeshi; Suzumiya,Junji

doi:10.3892/ol.2017.7713

TH588, an MTH1 inhibitor, enhances phenethyl isothiocyanate‑induced growth inhibition in pancreatic cancer cells

Authors:
- Fumiyoshi Ikejiri
- Yoshio Honma
- Takashi Kasukabe
- Takeshi Urano
- Junji Suzumiya
View Affiliations

Affiliations: The Department of Oncology/Hematology, Faculty of Medicine, Shimane University, Izumo, Shimane 693‑8501, Japan, The Department of Medical Education and Research, Faculty of Medicine, Shimane University, Izumo, Shimane 693‑8501, Japan, The Department of Biochemistry, Faculty of Medicine, Shimane University, Izumo, Shimane 693‑8501, Japan
Published online on: December 29, 2017 https://doi.org/10.3892/ol.2017.7713
Pages: 3240-3244

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemotherapy and radiotherapy are the most common approaches in cancer therapy. They may kill cancer cells through the generation of high levels of reactive oxygen species (ROS), which leads to oxidative DNA damage. However, tumor resistance to ROS is a problem in cancer therapy. MTH1 sanitizes oxidized dNTP pools to prevent the incorporation of damaged bases during DNA replication. Although MTH1 is non‑essential in normal cells, cancer cells require MTH1 activity to avoid the incorporation of oxidized dNTPs, which would result in DNA damage and cell death. By targeting a redox‑adaptation mechanism, MTH1 inhibition represents a novel therapeutic strategy against cancer. However, recent reports have indicated that growth inhibition by MTH1 inhibitors may be due to off‑target cytotoxic effects. TH588, one of the first‑in‑class MTH1 inhibitors, kills cancer cells by an off‑target effect. However, a low concentration of TH588 may effectively inhibit MTH1 activity without inhibiting cell proliferation. Phenethyl isothiocyanate (PEITC) is a dietary anticarcinogenic compound and an inducer of ROS. In the present study, it has been demonstrated that combined treatment with PEITC and TH588 effectively inhibited the growth of pancreatic cancer MIAPaCa‑2 and Panc‑1 cells. The antioxidant N‑acetylcysteine negated this synergistic growth inhibition. PEITC and TH588 cooperatively induced the formation of 8‑oxo‑deoxyguanine in nuclei and pH2AX foci, a marker of DNA damage. However, the combined effects are not associated with MTH1 mRNA expression in several cancer cell lines, suggesting that the possibility of an off‑target effect of TH588 cannot be eliminated. These results suggest that the combination of PEITC and TH588 has potential as a novel therapeutic strategy against pancreatic cancer.

View Figures

View References

1	Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 364:1817–1825. 2011. View Article : Google Scholar : PubMed/NCBI
2	Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, Lewis TA, Maglathin RL, Tolliday N and Jacks T: Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA. 108:pp. 8773–8778. 2011; View Article : Google Scholar : PubMed/NCBI
3	Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, Pelicano H, Chiao PJ, Achanta G, Arlinghaus RB, Liu J and Huang P: Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell. 10:241–252. 2006. View Article : Google Scholar : PubMed/NCBI
4	Henzel AF, Kimmelman AC, Stanger BZ, Bardeesy N and Depinho RA: Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. 20:1218–1249. 2006. View Article : Google Scholar : PubMed/NCBI
5	Wu X, Zhou QH and Xu K: Are isothiocyanates potential anti-cancer drugs? Acta Pharmacol Sin. 30:501–512. 2009. View Article : Google Scholar : PubMed/NCBI
6	Wu X, Kassie F and Mersch-Sundermann V: Induction of apoptosis in tumor cells by naturally occurring sulfur-containing compounds. Mutat Res. 589:81–102. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kasukabe T, Honma Y, Okabe-Kado J, Higuchi Y, Kato N and Kumakura S: Combined treatment with cotylenin A and phenethyl isothiocyanate induces strong antitumor activity mainly through the induction of ferroptotic cell death in human pancreatic cancer cells. Oncol Rep. 36:968–976. 2016. View Article : Google Scholar : PubMed/NCBI
8	Xiao D, Powolny AA, Moura MB, Kelley EE, Bommareddy A, Kim SH, Hahm ER, Normolle D, Van Houten B and Singh SV: Phenethyl isothiocyanate inhibits oxidative phosphorylation to trigger reactive oxygen species-mediated death of human prostate cancer cells. J Biol Chem. 285:26558–26569. 2010. View Article : Google Scholar : PubMed/NCBI
9	Topal MD and Baker MS: DNA precursor pool: A significant target for N-methyl-N-nitrosourea in C3H/10T1/2 clone 8 cells. Proc Natl Acad Sci USA. 79:pp. 2211–2215. 1982; View Article : Google Scholar : PubMed/NCBI
10	Yoshimura D, Sakumi K, Ohno M, Sakai Y, Furuichi M, Iwai S and Nakabeppu Y: An oxidized purine nucleoside triphosphatase, MTH1, suppresses cell death caused by oxidative stress. J Biol Chem. 278:37965–37973. 2003. View Article : Google Scholar : PubMed/NCBI
11	Sakai Y, Furuichi M, Takahashi M, Mishima M, Iwai S, Shirakawa M and Nakabeppu Y: A molecular basis for the selective recognition of 2-hydroxy-dATP and 8-oxo-dGTP by human MTH1. J Biol Chem. 277:8579–8587. 2002. View Article : Google Scholar : PubMed/NCBI
12	Kennedy CH, Pass HI and Mitchell JB: Expression of human MutT homologue (hMTH1) protein in primary non-small-cell lung carcinomas and histologically normal surrounding tissue. Free Radic Biol Med. 34:1447–1457. 2003. View Article : Google Scholar : PubMed/NCBI
13	Giribaldi MG, Munoz A, Halvorsen K, Patel A and Rai P: MTH1 expression is required for effective transformation by oncogenic HRAS. Oncotarget. 6:11519–11529. 2015. View Article : Google Scholar : PubMed/NCBI
14	Patel A, Burton DG, Halvorsen K, Balkan W, Reiner T, Perez-Stable C, Cohen A, Munoz A, Giribaldi MG, Singh S, et al: MutT homolog 1 (MTH1) maintains multiple KRAS-driven pro-malignant pathways. Oncogene. 34:2586–2596. 2015. View Article : Google Scholar : PubMed/NCBI
15	Gad H, Koolmeister T, Jemth AS, Eshtad S, Jacques SA, Ström CE, Svensson LM, Schultz N, Lundbäck T, Einarsdottir BO, et al: MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. Nature. 508:215–221. 2014. View Article : Google Scholar : PubMed/NCBI
16	Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, et al: Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 508:222–227. 2014. View Article : Google Scholar : PubMed/NCBI
17	Kawamura T, Kawatani M, Muroi M, Kondoh Y, Futamura Y, Aono H, Tanaka M, Honda K and Osada H: Proteomic profiling of small-molecule inhibitors reveals dispensability of MTH1 for cancer cell survival. Sci Rep. 6:265212016. View Article : Google Scholar : PubMed/NCBI
18	Kettle JG, Alwan H, Bista M, Breed J, Davies NL, Eckersley K, Fillery S, Foote KM, Goodwin L, Jones DR, et al: Potent and selective inhibitors of MTH1 probe its role in cancer cell survival. J Med Chem. 59:2346–2361. 2016. View Article : Google Scholar : PubMed/NCBI
19	Kawakami K, Hattori M, Inoue T, Maruyama Y, Ohkanda J, Kato N, Tongu M, Yamada T, Akimoto M, Takenaga K, et al: A novel fusicoccin derivative preferentially targets hypoxic tumor cells and inhibits tumor growth in xenografts. Anticancer Agents Med Chem. 12:791–800. 2012. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Song W, Zhou Y, Mao F, Lin Y, Guan J and Sun Q: Expression and function of MutT homolog 1 in distinct subtypes of breast cancer. Oncol Lett. 13:2161–2168. 2017. View Article : Google Scholar : PubMed/NCBI
21	Struthers L, Patel R, Clark J and Thomas S: Direct detection of 8-oxodeoxyguanosine and 8-oxoguanine by avidin and its analogues. Anal Biochem. 255:20–31. 1998. View Article : Google Scholar : PubMed/NCBI
22	Conners R, Hooley E, Clarke AR, Thomas S and Brady R: Recognition of oxidatively modified bases within the biotin-binding site by avidin. J Mol Biol. 357:263–274. 2006. View Article : Google Scholar : PubMed/NCBI
23	Goodman J and Hochstein P: Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin. Biochem Biophys Res Commun. 77:797–803. 1977. View Article : Google Scholar : PubMed/NCBI
24	Hattori M, Kawakami K, Akimoto M, Takenaga K, Suzumiya J and Honma Y: Antitumor effect of Japanese apricot extract (MK615) on human cancer cells in vitro and in vivo through a reactive oxygen species-dependent mechanism. Tumori. 99:239–248. 2013.PubMed/NCBI
25	Ishii Y, Hori Y, Sakai S and Honma Y: Control of differentiation and apoptosis of human myeloid leukemia cells by cytokinins and cytokinin nucleosides, plant redifferentiation-inducing hormones. Cell Growth Differ. 13:19–26. 2002.PubMed/NCBI
26	Wang JY, Jin L, Yan XG, Sherwin S, Farrelly M, Zhang YY, Liu F, Wang CY, Guo ST, Yari H, et al: Reactive oxygen species dictate the apoptotic response of melanoma cells to TH588. J Invest Dermatol. 136:2277–2286. 2016. View Article : Google Scholar : PubMed/NCBI
27	Tu Y, Wang Z, Wang X, Yang H, Zhang P, Johnson M, Liu N, Liu H, Jin W, Zhang Y and Cui D4: Birth of MTH1 as a therapeutic target for glioblastoma: MTH1 is indispensable for gliomatumorigenesis. Am J Transl Res. 8:2803–2811. 2016.PubMed/NCBI
28	Akiyama S, Saeki H, Nakashima Y, Iimori M, Kitao H, Oki E, Oda Y, Nakabeppu Y, Kakeji Y and Maehara Y: Prognostic impact of MutT homolog-1 expression on esophageal squamous cell carcinoma. Cancer Med. 6:258–266. 2017. View Article : Google Scholar : PubMed/NCBI
29	Zhu C, Hu W, Wu H and Hu X: No evident dose-response relationship between cellular ROS level and its cytotoxicity-a paradoxical issue in ROS-based cancer therapy. Sci Rep. 4:50292014. View Article : Google Scholar : PubMed/NCBI
30	Kumari V, Dyba MA, Holland RJ, Liang YH, Singh SV and Ji X: Irreversible inhibition of glutathione S-transferase by phenethyl isothiocyanate (PEITC), a dietary cancer chemopreventive phytochemical. PLoS One. 11:e01638212016. View Article : Google Scholar : PubMed/NCBI